ABSTRACT:
Using an analytical quality by design approach, the current work aimed to establish a robust, precise, accurate, and specific HPLC method for the quantification of empagliflozin in tablet dosage form and in bulk. By using both observation and head part examination, the fundamental boundaries were accurately determined. To create mathematical models, two independent factors—flow rate and wavelength—were used. Using a C18 segment with a portable stage that contained a mobile phase composition of 0.05 M potassium dihydrogen orthophosphate buffer pH 3 and acetonitrile in a ratio of (40:60 v/v) at a flow rate of 1.0 ml/min and column temperature of 40 °C, the optimised and expected data was achieved. These ideal circumstances allowed for the baseline drug separation with good resolution and a run time of less than 2.5 minutes. A PDA indicator at 228 nm was used to finish the discovery process. ICH Q2 (R1) guidelines were followed in the validation of the optimised assay settings. Because the results were found to be robust and specific, it was evident that the Quality by Design approach could be used to successfully optimise the RP-HPLC method for routine quantification of empagliflozin HCl in bulk and tablet format.
Cite this article:
Prerana Prakash Bhavsar, Subodh Anil Gangurde. RP-HPLC Method Development and Validation of Empagliflozin by using QbD Approach. Research Journal Pharmacy and Technology. 2025;18(11):5411-5. doi: 10.52711/0974-360X.2025.00780
Cite(Electronic):
Prerana Prakash Bhavsar, Subodh Anil Gangurde. RP-HPLC Method Development and Validation of Empagliflozin by using QbD Approach. Research Journal Pharmacy and Technology. 2025;18(11):5411-5. doi: 10.52711/0974-360X.2025.00780 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-11-42
REFERENCES:
1. Four phase III trials confirm benefits of BI’s Oral, Once-daily type 2 Diabetes therapy, and Genetic Engineering and Biotechnology News. 2010.
2. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus, Clin Endocrinol Metab. 2010; 95: 34–42.
3. FDA approves type 2 Diabetes drug from Boehringer Ingelheim and Lilly. 2011.
4. Christian Friedrich, Katrin Metzmann, Peter Rose, Michaela Mattheus, Sabine Pinnetti, and Hans J. Woerle. A Randomized, Open-Label. Crossover study to evaluate the pharmacokinetics of Empagliflozin and Linagliptin after co administration in healthy male volunteers, Clinical Therapeutics. 2013; 35: 22-24.
5. Tripathi K.D. Essential of Medical Pharmacology. 2013; 5: 515-16.
6. Diabetes (type 2)-Empagliflozin, Appraisal consultation document, NICE Technology Appraisal. 2014.
7. Joshua J Neumiller, Empagliflozin. A new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes, Drugs in Context. 2014; 3: 212-62.
8. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Diabetes Res Clin Pract. 2014; 103:137-149.
9. Ayoub BM. Development and validation of simple spectrophotometric and chemometric methods for simultaneous determination of empagliflozin and metformin: applied to recently approved pharmaceutical formulation. Spectrochim Acta A Mol Biomol Spectrosc. 2016; 5: 118–122
10. Ayoub BM. Application of spiking technique coupled with derivative spectrophotometry for the analysis of a novel anti-diabetic combination of two co-formulated drugs with highly different concentrations. Der Pharma Chem. 2016; 8: 12–14.
11. Padmaja N, Veerabhadram G. Method development and validation of RP-HPLC method for the estimation of empagliflozin in API. Int J Pharm Sci Res. 2016; 7: 724–727
12. Patil SD, Amurutkar SV, Upasani CD. Development and validation of stability indicating RP-HPLC method for empagliflozin. Asian J Pharm Anal. 2016; 6: 201–206
13. Padmaja N, Veerabhadram G. Development and validation of a novel stability-indicating RP-HPLC method for the determination of empagliflozin in bulk and pharmaceutical dosage form. Int J Pharm Sci Res. 2016; 7: 4523–4530.
14. Shyamala Nirmala K, Mounika J, Nandini B. Validated stability-indicating RP-HPLC method for determination of empagliflozin. Der Pharm Lett. 2016; 8: 457–464.
15. Jaiswal SH, Katariya MV, Katariya VR, Karva GS, Koshe K Validated stability indicating HPLC method for determination of process related impurities in empagliflozin drug substances. World J Pharm Res. 2017; 6: 1025–1037.
16. Khalil GA, Salama I, Gomma MS, Helal MA. Validated RP-HPLC method for simultaneous determination of canagliflozin, dapagliflozin, empagliflozin and metformin. Int J Pharm Chem Biol Sci. 2018; 8: 1–13.
17. Godasu S, Sreenivas S. A new validated RP-HPLC method for the determination of metformin HCl and empagliflozin in its bulk and pharmaceutical dosage. Int J Pharm Sci Res. 2017; 6: 903–917
18. Abdel-Ghany MF, Abdel-Aziz O, Ayad MF, Tadros MM. New LC–UV methods for pharmaceutical analysis of novel anti-diabetic combinations. Acta Chromatogr. 2017; 29: 448–452
19. Syed Irfan A, Bharath Rathna Kumar P. Stability indicating simultaneous estimation of metformin empagliflozin in pharmaceutical tablet dosage form by RP-HPLC. Asian J Res Chem. 2017; 10: 783–788.
20. Ayoub BM, Mowaka Shereen. LC–MS/MS determination of empagliflozin and metformin. J Chromatogr Sci. 2017; 55: 742–747.
21. Padmaja N, Veerabhadram G. A novel stability indicating RP-UPLCDAD method for determination of metformin and empagliflozin in bulk and tablet dosage form. Orient J Chem. 2017; 33: 1949–1958
22. Vinay Kumar D, Seshagiri Rao JVLN. A new validated stability indicating RP-HPLC method for simultaneous estimation of metformin hydrochloride and empagliflozin in tablet dosage forms. IRJPMS. 2018; 1: 16–22
23. Ayoub BM. UPLC simultaneous determination of empagliflozin, linagliptin and metformin. RSC Adv. 2015; 5: 95703–95709.
24. Madan Mohan reddy M, Gowri Sankar D, Seshagiri Rao JVLN. Stress degradation studies and development of validation stability indicating assay method by RP-HPLC for simultaneous estimation of metformin and empagliflozin in presence of degradation products as per ICH guidelines. J Sci Res Pharm. 2017; 2: 20–33
25. Donepudi Sharmila, Achanta Suneetha. Validated HPLC-UV method for simultaneous estimation of linagliptin and empagliflozin in human plasma. Int J Appl Pharm. 2018; 10: 56–61
26. Padmaja N, Desalegn T, Sharathbabu M, Veerabhadram G. New validated RP-HPLC method for the estimation of empagliflozin in human plasma. Int J Pharm Sci Res. 2018; 9(11): 4885–4889
27. Ayoub BM, Mowaka S, Elzanfaly ES, Ashoush N, Elmazar MM, Mousa SA. Pharmacokinetic evaluation of empagliflozin in healthy egyptian volunteers using LC–MS/MS and comparison with other ethnic populations. Sci Rep. 2017; 7: 2583–2591.
28. Patil AS, Pethe AM. Quality by Design (QbD): A new concept for development of quality pharmaceuticals. Int J Qual Assur. 2013; 4: 13-19.
29. Vogt FG, Kord AS. Development of quality by design analytical methods. J Pharm Sci. 2011; 100: 797-812.